Skip to content
OpenCapital
Get started

Beam Therapeutics BEAM Cash ratio

Cash ratio at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
1.4×+0.2×
Arrowhead Research logo
Arrowhead ResearchARWR
0.6×-0.2×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.5×+0.1×
MGN
MagniteMGNI
0.1×-0.2×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
1.8×+0.6×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
3.1×+1.1×

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Calculated from Beam Therapeutics’s reported figures.

cash and equivalents/total current liabilities=3.9×

Based on the most recent quarter.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's cash ratio?
Beam Therapeutics (BEAM) reported cash ratio of 3.9× in Q1 2026.
How has Beam Therapeutics's cash ratio changed year-over-year?
Beam Therapeutics's cash ratio increased by 3.7% year-over-year, from 3.7× to 3.9×.
What is the long-term trend for Beam Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Beam Therapeutics's cash ratio has grown at a 13.9% compound annual growth rate (CAGR), from 1.6× to 3×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.